U.S.-Based national sentinel surveillance study for the epidemiology of clostridium difficile-associated diarrheal isolates and their susceptibility to fidaxomicin

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6437-6443

  Snydman, D R ^a,b   McDermott, L A ^a   Jacobus, N V ^a   Thorpe, C ^a,b   Stone, S ^a   Jenkins, S G ^c   Goldstein, E J C ^d   Patel, R ^e   Forbes, B A ^f   Mirrett, S ^g   Johnson, S ^h,i   Gerding, D N ^h,i  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d R M ALDEN RESEARCH LABORATORY   (United States)

^e MAYO CLINIC   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^h HINES VA HOSPITAL   (United States)

ⁱ LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; CHLORAMPHENICOL; CLINDAMYCIN; FIDAXOMICIN; IMIPENEM; METRONIDAZOLE; MOXIFLOXACIN; RIFAMPICIN; RIFAXIMIN; TIGECYCLINE; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DIARRHEA; EPIDEMIC; GENE DELETION; GEOGRAPHICAL VARIATION (SPECIES); MIC50; MIC90; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; RESTRICTION MAPPING; TCDA GENE; TCDB GENE; TCDC GENE; UNITED STATES; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SENTINEL SURVEILLANCE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE; DIARRHEA; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FLUOROQUINOLONES; GENES, BACTERIAL; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MULTIPLEX POLYMERASE CHAIN REACTION; SENTINEL SURVEILLANCE; UNITED STATES; VANCOMYCIN;

EID: 84942872065     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00845-15     Document Type: Article

References (35)

1. Labbe AC, Poirier L, MacCannell D, Louie T, Savoie M, Beliveau C, Laverdiere M, Pepin J. 2008. Clostridium difficile infections in a Canadian tertiary care hospital before and during regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 52:3180-3187. http://dx.doi.org/10.1128/AAC.00146-08.
2. Taori SK, Hall V, Poxton IR. 2010. Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004. J Med Microbiol 59:338-344. http://dx.doi.org/10.1099/jmm.0.014829-0.
3. Goldstein EJG, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. 2011. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother 55:5194-5199. http://dx.doi.org/10.1128/AAC.00625-11.
4. Baines SD, O'Connor R, Freeman J, Fawley WN, Harmanus C, Mastrantonio P, Kuijper EJ, Wilcox WH. 2008. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 62:1046-1052. http://dx.doi.org/10.1093/jac/dkn313.
5. Citron DM, Babakhani F, Goldstein EJC, Nagaro K, Sambol S, Sears P, Shue Y-K, Gerding DN. 2009. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe 15:234-236. http://dx.doi.org/10.1016/j.anaerobe.2009.09.005.
6. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422-431. http://dx.doi.org/10.1056/NEJMoa0910812.
7. Killgore GE, Thompson AD, Johnson S, Brazier J, Kuijper E, Pepin J, Frost EH, Savelkoul P, Nicholson B, van den Berg RJ, Kato H, Sambol SP, Zukowski W, Woods C, Limbago B, Gerding DN, McDonald LC. 2008. Comparison of seven techniques for typing international epidemic strains of C. difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J Clin Microbiol 46:431-437. http://dx.doi.org/10.1128/JCM.01484-07.
8. Manzo CE, Merrigan MM, Johnson S, Gerding DN, Riley TV, Silva J, Jr, Brazier JS, International Clostridium difficile Study Group. 2014. International typing study of Clostridium difficile. Anaerobe 28:4-7. http://dx.doi.org/10.1016/j.anaerobe.2014.04.005.
9. George WL, Sutter VL, Citron D, Finegold SM. 1979. Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol 9:214-219.
10. Jousimies-Somer HR, Summanen P, Citron DM, Baron EJ, Wexler HA, Finegold SM. 2002. Wadsworth-KTL anaerobic bacteriology manual, 6th ed. Star Publishing Company. Belmont, CA.
11. Clinical and Laboratory Standards Institute. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard. CLSI publication number M11-A8. Clinical and Laboratory Standards Institute. Wayne, PA.
12. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
13. European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters, v5.0. 2015. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Breakpoint-tables/v-5.0-Breakpoint-Table-01.pdf.
14. Pfizer. 2015. Tygacil: package monograph. Pfizer, Kirkland, Quebec, Canada. http://labeling.pfizer.com/showlabeling.aspx?id=491.
15. Persson S, Jensen JN, Olsen KE. 2011. Multiplex PCR method for detection of Clostridium difficile tcdA, tcdB, cdtA, and cdtB and internal in-frame deletion of tcdC. J Clin Microbiol 49:4299-4300. http://dx.doi.org/10.1128/JCM.05161-11.
16. Persson S, Torpdahl M, Olsen KEP. 2008. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clin Microbiol Infect 14:1057-1064. http://dx.doi.org/10.1111/j.1469-0691.2008.02092.x.
17. Moncrief JS, Zheng L, Neville LM, Lyerly DM. 2000. Genetic characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates by PCR. J Clin Microbiol 38:3072-3075.
18. Braun V, Hudsberger T, Leukel P, Sauerborn M, von Eichel-Streiber C. 1996. Definition of the single integration site of the pathogenicity locus in Clostridium difficile. Gene 181:29-38. http://dx.doi.org/10.1016/S0378-1119 (96) 00398-8.
19. Carter GP, Lyras D, Allen DL, Mackin KE, Howarth PM, O'Connor JR, Rood JE. 2007. Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator. J Bacteriol 189:7290-7301. http://dx.doi.org/10.1128/JB.00731-07.
20. Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebaihia M, Quail MA, Rose G, Gerding DN, Gibert M, Popoff MR, Parkhill J, Dougan G, Wren BW. 2009. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 10:R102. http://dx.doi.org/10.1186/gb-2009-10-9-r102.
21. Sullivan NM, Pellett S, Wilkins TD. 1992. Purification and characterization of toxins AandB of Clostridium difficile. Infect Immun 35:1032-1040.
22. Clabots CR, Johnson S, Bettin KM, Mathie PA, Mulligan ME, Schaberg DS, Peterson LR, Gerding DN. 1993. Development of a rapid and efficient endonuclease analysis typing system for Clostridium difficileand correlation with other correlation with other typing systems. J Clin Microbiol 31:1870-1895.
23. Freeman J, Vernon J, Morris K, Nicholson S, Todhunter S, Longshaw C, Wilcox MH, Pan-European Longitudinal Surveillance of Antibiotic Resistance among Prevalent Clostridium difficile Ribotypes Study Group. 2015. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin Microbiol Infect 21:248.e9-248.e16.
24. Goldstein EJC, Babakhani F, Citron DM. 2012. Antimicrobial activities of fidaxomicin. Clin Infectious Dis 55(Suppl 2):S143-S148. http://dx.doi.org/10.1093/cid/cis339.
25. Huang H, Fang H, Weintraub A, Nord CE. 2009. Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile in Shanghai and Stockholm. Clin Microbiol Infect 15:1170-1173. http://dx.doi.org/10.1111/j.1469-0691.2009.02992.x.
26. Tickler IA, Goering RV, Whitmore JD, Lynn ANW, Persing DH, Tenover FC. 2014. Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013. Antimicrob Agents Chemother 58:4214-4218. http://dx.doi.org/10.1128/AAC.02775-13.
27. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson SJ, Gerding DN. 2007. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983-2004. Antimicrob Agents Chemother 51:2716-2719. http://dx.doi.org/10.1128/AAC.01623-06.
28. Tenover FC, Tickler IA, Persing DH. 2012. Antimicrobial-resistant strains of Clostridium difficile from North America. Antimicrob Agents Chemother 56:2929-2932. http://dx.doi.org/10.1128/AAC.00220-12.
29. Cheknis AK, Sambol SP, Davidson DM, Nagaro KJ, Mancini MC, Aida Hidalgo-Arroyo G, Brazier JS, Johnson S, Gerding DN. 2009. Distribution of Clostridium difficile strains from a North American, European, and Australian trial of treatment for C. difficile infections: 2005-2007. Anaerobe 15:230-233. http://dx.doi.org/10.1016/j.anaerobe.2009.09.001.
30. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. 2015. Burden of Clostridium difficile infection in the United States. N Engl J Med 372:825-834. http://dx.doi.org/10.1056/NEJMoa1408913.
31. Waslawski S, Lo ES, Ewing SA, Young VB, Aronoff DM, Sharp SE, Novak-Weekley SM, Crist AE Jr, Dunne WM, Hoppe-Bauer J, Johnson M, Brecher SM, Newton DW, Walk ST. 2013. Clostridium difficile ribotype diversity at six health care institutions in the United States. J Clin Microbiol 51:1938-1941. http://dx.doi.org/10.1128/JCM.00056-13.
32. Tenover FC, Akerlund T, Gerding DN, Goering RV, Boström T, Jonsson AM, Wong E, Wortman AT, Persing DH. 2011. Comparison of strain typing results for Clostridium difficile isolates from North America. J Clin Microbiol 49:1831-1837. http://dx.doi.org/10.1128/JCM.02446-10.
33. Cornely OA, Crook DW, Esposito R, Poirer A, Somero MS, Weiss K, Sears P, Gorbach S, OPT-80-004 Clinical Study Group. 2012. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada and the U S A. Lancet Infect Dis 12:281-289. http://dx.doi.org/10.1016/S1473-3099 (11) 70374-7.
34. Chesnel L, Sambol S, Gerding D, Patino H, Thorne G, Silverman J. 2012. Treatment of CDAD with oral CB-183, 315: time to recurrence, relapse and reinfection rates compared with vancomycin, abstr 1439. Abstr. 22nd Eur. Cong. Clin. Microbiol. Infect. Dis., London, United Kingdom.
35. Louie T, Buitrago M, Cornely OA, Kracker H, Rangaraju M, Charef P. 2013. Multicentre, double-blind, randomized, phase 2 study evaluating the novel antibiotic, cadazolid, in subjects with Clostridium difficileassociated diarrhea, abstrLB2956. Abstr. 23rd Eur. Cong. Clin. Microbiol. Infect. Dis., Berlin, Germany.